The KC-46 was to be the ideal candidate for a fixed-price development program. Instead, it has cost Boeing billions, and made industry wary of such deals.
The ruling upholds a preliminary injunction issued by a federal judge in January 2022. At that point, nearly 98% of covered employees had been vaccinated.